Shim C, Williams M H
Ann Intern Med. 1980 Sep;93(3):428-31. doi: 10.7326/0003-4819-93-3-428.
We tested the relative efficacy of bronchodilators delivered in aerosol and in oral form in 17 patients with asthma in a double-blind randomized sequence. Treatment consisted of a 20-mg tablet of metaproterenol sulfate, five puffs of metaproterenol aerosol (0.65 mg in each puff for a total of 3.25 mg) administered 20 minutes apart between puffs, a combination of both, and placebos. Bronchodilator response measured by forced expiratory volume in 1 second (FEV1) was significantly greater on the aerosol and the combined regimen than on the oral and placebo regimen. The combined regimen produced a greater bronchodilator response than the aerosol alone, but the difference was not significant. Side effects were frequent after oral medication but absent after the aerosol. Sequential inhalation of aerosol is the preferred route of administration of adrenergic bronchodilator drugs in asthma.
我们采用双盲随机序列法,对17例哮喘患者测试了气雾剂和口服形式的支气管扩张剂的相对疗效。治疗包括20毫克硫酸间羟异丙肾上腺素片剂、间隔20分钟吸入5次间羟异丙肾上腺素气雾剂(每次吸入0.65毫克,共3.25毫克)、两者联合使用以及安慰剂。通过第1秒用力呼气量(FEV1)测量的支气管扩张反应,气雾剂和联合治疗方案比口服和安慰剂方案显著更大。联合治疗方案产生的支气管扩张反应比单独使用气雾剂更大,但差异不显著。口服药物后副作用频繁,但气雾剂治疗后无副作用。在哮喘中,顺序吸入气雾剂是肾上腺素能支气管扩张药物的首选给药途径。